Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations

Triana Espinosa-Jiménez1,2,3, Oriol Busquets4, Amanda Cano2,5,6,7

  • 1Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.

Insights

Loss of Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) impairs memory by affecting neuronal structure and increasing neuroinflammation. Obesity exacerbates these PPARβ/δ-related memory deficits.

Area of Science:

  • Neuroscience
  • Metabolic disease research

Background:

  • Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) is abundant in the CNS and involved in microglial homeostasis and metabolism.
  • Disturbances in PPARβ/δ signaling are linked to memory impairment, but its specific role in neuronal function and memory is underexplored.

Purpose of the Study:

  • To investigate the role of PPARβ/δ in neuropathological pathways associated with memory impairment.
  • To determine if obesity, a risk factor for memory loss, modulates these neuropathological markers in the context of PPARβ/δ signaling.

Main Methods:

  • Utilized PPARβ/δ knockout (PPARβ/δ-/-) and wild-type (WT) mice fed either a control diet (CT) or a high-fat diet (HFD).
  • Assessed memory function using the novel object recognition test (NORT) and metabolic function via glucose and insulin tolerance tests.
  • Examined neuronal and synaptic structure, gliosis, and neuroinflammation in the hippocampus using techniques like GolgiStain and immunofluorescence.

Main Results:

  • PPARβ/δ-/- mice exhibited reduced dendritic spine density and synaptic markers, correlating with impaired performance in the NORT.
  • Absence of PPARβ/δ led to increased hippocampal gliosis, characterized by astrocyte and microglial activation and elevated neuroinflammatory biomarkers.
  • Alterations in the hippocampal insulin receptor pathway were observed in PPARβ/δ-/- mice. High-fat diet modulated some, but not all, of these deficits, sometimes exacerbating them.

Conclusions:

  • Loss of PPARβ/δ significantly impacts neuronal and synaptic integrity, contributing to memory dysfunction.
  • PPARβ/δ deficiency promotes neuroinflammation and alters hippocampal insulin signaling.
  • PPARβ/δ emerges as a potential therapeutic target for treating memory impairment, with its role being influenced by metabolic factors like obesity.

Related Concept Videos

Protein Import into the Peroxisomes01:27

Protein Import into the Peroxisomes

Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
3.6K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
663
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
199